Publicaciones en colaboración con investigadores/as de Centro Nacional de Investigaciones Oncológicas (15)

2024

  1. Metabolomic profile of neuroendocrine tumors identifies methionine, porphyrin, and tryptophan metabolisms as key dysregulated pathways associated with patient survival

    European Journal of Endocrinology, Vol. 190, Núm. 1, pp. 62-74

2023

  1. Advances in the Treatment of Gastroenteropancreatic Neuroendocrine Carcinomas: Are we Moving Forward?

    Endocrine reviews, Vol. 44, Núm. 4, pp. 724-736

  2. MicroRNA signature and integrative omics analyses define prognostic clusters and key pathways driving prognosis in patients with neuroendocrine neoplasms

    Molecular Oncology, Vol. 17, Núm. 4, pp. 582-597

2022

  1. Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors

    Journal for immunotherapy of cancer, Vol. 10, Núm. 3

2021

  1. Comprehensive plasma metabolomic profile of patients with advanced neuroendocrine tumors (Nets). diagnostic and biological relevance

    Cancers, Vol. 13, Núm. 11

  2. Multidisciplinary practice guidelines for the diagnosis, genetic counseling and treatment of pheochromocytomas and paragangliomas

    Clinical and Translational Oncology, Vol. 23, Núm. 10, pp. 1995-2019

  3. Sunitinib and Evofosfamide (TH-302) in Systemic Treatment-Naïve Patients with Grade 1/2 Metastatic Pancreatic Neuroendocrine Tumors: The GETNE-1408 Trial

    Oncologist, Vol. 26, Núm. 11, pp. 941-949

2020

  1. How can bioinformatics contribute to the routine application of personalized precision medicine?

    Expert Review of Precision Medicine and Drug Development

  2. Oxidized lipids in the metabolic profiling of neuroendocrine tumors – Analytical challenges and biological implications

    Journal of Chromatography A, Vol. 1625

2019

  1. The correlation between immune subtypes and consensus molecular subtypes in colorectal cancer identifies novel tumour microenvironment profiles, with prognostic and therapeutic implications

    European Journal of Cancer, Vol. 123, pp. 118-129

2018

  1. Prognostic and predictive biomarkers for somatostatin analogs, peptide receptor radionuclide therapy and serotonin pathway targets in neuroendocrine tumours

    Cancer Treatment Reviews, Vol. 70, pp. 209-222

2017

  1. Prognostic relevance of Src activation in stage II-III colon cancer

    Human Pathology, Vol. 67, pp. 119-125

2015

  1. Pazopanib in pretreated advanced neuroendocrine tumors: A phase II, open-label trial of the Spanish Task Force Group for Neuroendocrine Tumors (GETNE)

    Annals of Oncology, Vol. 26, Núm. 9, pp. 1987-1993

2009

  1. Inhibiting PI3K as a therapeutic strategy against cancer

    Clinical and Translational Oncology, Vol. 11, Núm. 9, pp. 572-579

2007

  1. Prognostic value of KIT expression in small cell lung cancer

    Lung Cancer, Vol. 56, Núm. 3, pp. 405-413